5.32306

PAS Kinase Inhibitor, BioE-1115

• Sinónimos: PAS Kinase Inhibitor, BioE-1115, PASK Inhibitor, 2-(4-Fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid, BioE1115, Per-Arnt-Sim Domain Kinase Inhibitor, PAS Domain Kinase Inhibitor
• Fórmula empírica (notación de Hill): C₁₉H₁₈FN₃O₂
• Número de CAS: 1268863-35-9
• Peso molecular: 339.36
• MDL number: MFCD06386715
• UNSPSC Code: 51111800
• NACRES: NA.77

Propiedades

• assay: ≥97% (HPLC)
• Quality Level: 100
• form: powder
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: yellow
• solubility: DMSO: 50 mg/mL
• storage temp.: 2-8°C

Descripción

General description

A cell-permeable quinoxaline-carboxylic acid compound that acts as a selective PAS kinase/PASK inhibitor (IC₅₀ ~ 4 nM) with little or no potency against a panel of 49 other kinases (IC₅₀ ≥ 10 µM) and effectively inhibits cellular PASK-T307 autophosphorylation (IC₅₀ ~ 1 µM; 16 h drug treatment in PASK-transfected HEK293T cultures with 1% FBS). Similar to siRNA-mediated PASK knockdown, BioE-1115 treatment is shown to effectively prevent sterol regulatory element binding protein SREBP-1c maturation without affecting Akt/mTOR pathway signaling, resulting in impaired cellular SREBP transcription activity in HepG2 cultures (% inhibition/[drug] = 40%/30 µM & & 65%/50 µM by SRE-Luc reporter assay; overnight drug treatment prior to 100 nM insulin stimulation for 6 h). Oral administration is reported to effectively reduce high-frucose diet/HFrD-induced dyslipidemia (% reduction of liver triglyceride/serum triacylglyerol/dose = 48/26/30 mg kg^-1 & 63/55/100 mg kg^-1; Daily oral dosage administered in the last wk of a 3 wk HFrD period, followed by a 24 h fasting and a 12 refed period prior to tissue collection) and insulin resistance (% reduction of serum glucose/insulin/dose = 23/14/30 mg kg^-1 & 28/31/100 mg kg^-1) in rats by selectively suppressing SREBP-1 maturation and thereby inhibiting SREBP-1c, but not SRREBP-2, target genes transcription in liver, but not in abdominal fat or gastrocnemius muscle in vivo (% Gpat1/Fasn/Scd1/Acc1/Fae mRNA reduction/plasma [BioE-1115] in µg/mL/dose = 40/34/36/27/34/2.07/10 mg kg^-1, 59/56/51/48/54/7.65/30 mg kg^-1, 76/5967/62/74/42.2/100 mg kg^-1) without affecting liver or body weight.

A cell-permeable, orally available, non-toxic quinoxaline-carboxylic acid based compound that acts as a highly potent, selective, and reversible inhibitor of Per-Arnt-Sim Kinase (PASK; IC₅₀ ~ 4 nM). Exhibits excellent selectivity over 49 other kinases (IC₅₀ >10 µM) and displays about 2,500-fold greater potency for PASK over casein kinase 2α. Blocks PASK autophosphorylation at Thr307 in a dose-dependent manner (IC₅₀ ~ 1 µM) without affecting the insulin-induced phosphorylation of either Akt or S6K. Effectively blocks the maturation of SREBP-1 in hepatic tissue of high fructose fed wild-type Sprague-Dawley rats. Shown to normalize hepatic and serum triglyceride levels, reduce blood glucose levels, and partially reverse insulin resistance in animal models (30 mg/kg. p.o.).

Please note that the molecular weight for this compound is batch-specific due to variable water content.

BioE-1115, PASKi

Biochem/physiol Actions

Cell permeable: yes

Primary Target
PASK

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Wu, X., et al. 2014. Cell Rep.8, 242.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable